Found: 52
Select item for more details and to access through your institution.
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 7, p. 1845, doi. 10.1007/s00432-019-02918-y
- By:
- Publication type:
- Article
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 3, p. 599, doi. 10.1007/s00432-018-2810-6
- By:
- Publication type:
- Article
Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Effects of Tamoxifen on the Female Genital Tract.
- Published in:
- Annals of the New York Academy of Sciences, 1991, v. 622, n. 1, p. 469, doi. 10.1111/j.1749-6632.1991.tb37890.x
- By:
- Publication type:
- Article
Socioeconomic status and quality of life of women with family history of breast cancer attending an oncogenetic counseling clinic - a comparison with general population.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 1, p. 86, doi. 10.1080/02841860802343182
- By:
- Publication type:
- Article
Predictors of return to work ten months after primary breast cancer surgery.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 1, p. 93, doi. 10.1080/02841860802477899
- By:
- Publication type:
- Article
Factors associated with return to work after breast cancer treatment.
- Published in:
- Acta Oncologica, 2007, v. 46, n. 1, p. 90, doi. 10.1080/02841860600857318
- By:
- Publication type:
- Article
Randomized Trial of Adjuvant Tamoxifen and/or Goserelin in Premenopausal Breast Cancer-Self-rated Physiological Effects and Symptoms.
- Published in:
- Acta Oncologica, 2000, v. 39, n. 8, p. 959, doi. 10.1080/02841860050215945
- By:
- Publication type:
- Article
Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival.
- Published in:
- Acta Oncologica, 1999, v. 38, n. 5, p. 597, doi. 10.1080/028418699431186
- By:
- Publication type:
- Article
A Descriptive Study of Pulmonary Complications After Postoperative Radiation Therapy in Node-Positive Stage II Breast Cancer.
- Published in:
- Acta Oncologica, 1997, v. 36, n. 5, p. 509, doi. 10.3109/02841869709001307
- By:
- Publication type:
- Article
17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer.
- Published in:
- PLoS ONE, 2012, v. 7, n. 7, p. 1, doi. 10.1371/journal.pone.0040568
- By:
- Publication type:
- Article
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-020-00210-8
- By:
- Publication type:
- Article
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2017, v. 3, n. 1, p. N.PAG, doi. 10.1038/s41523-017-0037-3
- By:
- Publication type:
- Article
Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4844, doi. 10.3390/cancers14194844
- By:
- Publication type:
- Article
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide.
- Published in:
- Cancer (0008543X), 1998, v. 83, n. 5, p. 936, doi. 10.1002/(SICI)1097-0142(19980901)83:5<936::AID-CNCR20>3.0.CO;2-V
- By:
- Publication type:
- Article
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 168, n. 1, p. 17, doi. 10.1007/s10549-017-4508-x
- By:
- Publication type:
- Article
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 166, n. 2, p. 593, doi. 10.1007/s10549-017-4428-9
- By:
- Publication type:
- Article
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 160, n. 2, p. 313, doi. 10.1007/s10549-016-4007-5
- By:
- Publication type:
- Article
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 153, n. 1, p. 31, doi. 10.1007/s10549-015-3516-y
- By:
- Publication type:
- Article
Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 145, n. 1, p. 61, doi. 10.1007/s10549-014-2936-4
- By:
- Publication type:
- Article
C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 145, n. 1, p. 73, doi. 10.1007/s10549-014-2933-7
- By:
- Publication type:
- Article
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 138, n. 2, p. 467, doi. 10.1007/s10549-013-2457-6
- By:
- Publication type:
- Article
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 137, n. 2, p. 397, doi. 10.1007/s10549-012-2376-y
- By:
- Publication type:
- Article
Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 137, n. 1, p. 297, doi. 10.1007/s10549-012-2337-5
- By:
- Publication type:
- Article
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 133, n. 1, p. 367, doi. 10.1007/s10549-012-1961-4
- By:
- Publication type:
- Article
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 130, n. 2, p. 553, doi. 10.1007/s10549-011-1594-z
- By:
- Publication type:
- Article
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 128, n. 3, p. 713, doi. 10.1007/s10549-010-1058-x
- By:
- Publication type:
- Article
Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 128, n. 3, p. 755, doi. 10.1007/s10549-011-1593-0
- By:
- Publication type:
- Article
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 126, n. 2, p. 421, doi. 10.1007/s10549-010-1202-7
- By:
- Publication type:
- Article
Impact of comorbidity on management and mortality in women diagnosed with breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2010, v. 135, n. 1, p. 281, doi. 10.1007/s10549-012-2176-4
- By:
- Publication type:
- Article
Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.
- Published in:
- Breast Cancer Research & Treatment, 2010, v. 121, n. 3, p. 679, doi. 10.1007/s10549-009-0615-7
- By:
- Publication type:
- Article
Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
- Published in:
- Breast Cancer Research & Treatment, 2008, v. 107, n. 1, p. 71
- By:
- Publication type:
- Article
Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 12, p. 2072, doi. 10.1002/ijc.33969
- By:
- Publication type:
- Article
VAV3 mediates resistance to breast cancer endocrine therapy.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 3, p. 1, doi. 10.1186/bcr3664
- By:
- Publication type:
- Article
VAV3 mediates resistance to breast cancer endocrine therapy.
- Published in:
- 2014
- By:
- Publication type:
- journal article
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
- Published in:
- Breast Cancer Research, 2013, v. 15, n. 5, p. 2, doi. 10.1186/bcr3557
- By:
- Publication type:
- Article
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
- Published in:
- International Journal of Oncology, 2015, v. 47, n. 4, p. 1311, doi. 10.3892/ijo.2015.3108
- By:
- Publication type:
- Article
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Family History, and Impact on Clinical Presentation and Prognosis, in a Population-based Breast Cancer Cohort from the Stockholm County.
- Published in:
- Familial Cancer, 2006, v. 5, n. 4, p. 309, doi. 10.1007/s10689-006-7851-3
- By:
- Publication type:
- Article
Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 6, p. e2114904, doi. 10.1001/jamanetworkopen.2021.14904
- By:
- Publication type:
- Article
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer.
- Published in:
- Journal of Pathology: Clinical Research, 2017, v. 3, n. 1, p. 38, doi. 10.1002/cjp2.56
- By:
- Publication type:
- Article
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.
- Published in:
- Acta Oncologica, 2017, v. 56, n. 4, p. 614, doi. 10.1080/0284186X.2016.1273547
- By:
- Publication type:
- Article
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00688-6
- By:
- Publication type:
- Article
Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study.
- Published in:
- Oncologist, 2013, v. 18, n. 7, p. 812, doi. 10.1634/theoncologist.2013-0091
- By:
- Publication type:
- Article
RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer.
- Published in:
- Oncology Letters, 2020, v. 19, n. 1, p. 52, doi. 10.3892/ol.2019.11109
- By:
- Publication type:
- Article
IP6K2 predicts favorable clinical outcome of primary breast cancer.
- Published in:
- Molecular & Clinical Oncology, 2021, v. 14, n. 5, p. N.PAG, doi. 10.3892/mco.2021.2256
- By:
- Publication type:
- Article
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer.
- Published in:
- Molecular & Clinical Oncology, 2020, v. 12, n. 5, p. 415, doi. 10.3892/mco.2020.2014
- By:
- Publication type:
- Article